Skip to main content

Advertisement

SpringerLink
Log in

Recent topics in fibroblast activation protein inhibitor-PET/CT: clinical and pharmacological aspects

  • Review Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Recently, positron emission tomography (PET) with fibroblast activation protein inhibitor (FAPI) has gained significant attention as an advanced tumor diagnostic imaging tool. FAPI PET has a promising potential owing to its ability to accurately depict most malignant tumors. It has an accuracy that is comparable to or surpassing the diagnostic accuracy of PET using 18F-fluorodeoxyglucose (FDG). Moreover, FAPI PET can identify malignant lesions that may be inconclusive on FDG PET. Beyond its application in neoplastic disorders, there have been encouraging reports suggesting the utility of FAPI PET in non-neoplastic conditions such as respiratory or cardiac diseases. This article aimed to provide a comprehensive overview of the recently published articles investigating FAPI and discuss its clinical utility with an emphasis on its application in tumor diagnostics. Numerous radiopharmaceutical FAPIs, including 18F- and 68Ga-labeled compounds, have been developed, and they offer various advantages and applications. With the progress in the FAPI PET synthesis to enhance accumulation and retention in pathological lesions, future studies are expected to provide valuable data on its therapeutic efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ballal S, Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S, et al. Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers. Eur J Nucl Med Mol Imaging. 2021;48(6):1915–31.

    CAS  PubMed  Google Scholar 

  2. Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60(6):801–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Sollini M, Kirienko M, Gelardi F, Fiz F, Gozzi N, Chiti A. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48(13):4396–414.

    PubMed  Google Scholar 

  4. Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. 68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60(3):386–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Zhao L, Pang Y, Zheng H, Han C, Gu J, Sun L, et al. Clinical utility of [(68)Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2021;48(11):3606–17.

    CAS  PubMed  Google Scholar 

  6. Qin C, Liu F, Huang J, Ruan W, Liu Q, Gai Y, et al. A head-to-head comparison of (68)Ga-DOTA-FAPI-04 and (18)F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study. Eur J Nucl Med Mol Imaging. 2021;48(10):3228–37.

    CAS  PubMed  Google Scholar 

  7. Linz C, Brands RC, Kertels O, Dierks A, Brumberg J, Gerhard-Hartmann E, et al. Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity - initial experience and comparison to [(18)F]FDG PET/CT and MRI. Eur J Nucl Med Mol Imaging. 2021;48(12):3951–60.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Fu H, Wu J, Huang J, Sun L, Wu H, Guo W, et al. 68Ga fibroblast activation protein inhibitor PET/CT in the detection of metastatic thyroid cancer: comparison with 18F-FDG PET/CT. Radiology. 2022;304(2):397–405.

    PubMed  Google Scholar 

  9. Zhou X, Wang S, Xu X, Meng X, Zhang H, Zhang A, et al. Higher accuracy of [(68) Ga]Ga-DOTA-FAPI-04 PET/CT comparing with 2-[(18)F]FDG PET/CT in clinical staging of NSCLC. Eur J Nucl Med Mol Imaging. 2022;49(8):2983–93.

    CAS  PubMed  Google Scholar 

  10. Pang Y, Zhao L, Shang Q, Meng T, Zhao L, Feng L, et al. Positron emission tomography and computed tomography with [(68)Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022;49(4):1322–37.

    CAS  PubMed  Google Scholar 

  11. Zhang Z, Jia G, Pan G, Cao K, Yang Q, Meng H, et al. Comparison of the diagnostic efficacy of (68) Ga-FAPI-04 PET/MR and (18)F-FDG PET/CT in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022;49(8):2877–88.

    CAS  PubMed  Google Scholar 

  12. Shou Y, Xue Q, Yuan J, Zhao J. 68Ga-FAPI-04 PET/MR is helpful in differential diagnosis of pancreatitis from pancreatic malignancy compared to 18F-FDG PET/CT: a case report. Eur J Hybrid Imaging. 2021;5(1):12.

    PubMed  PubMed Central  Google Scholar 

  13. Kömek H, Can C, Kaplan İ, Gündoğan C, Kepenek F, Karaoglan H, et al. Comparison of [(68) Ga]Ga-DOTA-FAPI-04 PET/CT and [(18)F]FDG PET/CT in colorectal cancer. Eur J Nucl Med Mol Imaging. 2022;49(11):3898–909.

    PubMed  Google Scholar 

  14. Lin R, Lin Z, Chen Z, Zheng S, Zhang J, Zang J, et al. [(68)Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2022;49(8):2960–71.

    CAS  PubMed  Google Scholar 

  15. Kuten J, Levine C, Shamni O, Pelles S, Wolf I, Lahat G, et al. Head-to-head comparison of [(68)Ga]Ga-FAPI-04 and [(18)F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma. Eur J Nucl Med Mol Imaging. 2022;49(2):743–50.

    CAS  PubMed  Google Scholar 

  16. Jiang D, Chen X, You Z, Wang H, Zhang X, Li X, et al. Comparison of [(68) Ga]Ga-FAPI-04 and [(18)F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study. Eur J Nucl Med Mol Imaging. 2022;49(2):732–42.

    CAS  PubMed  Google Scholar 

  17. Wu C, Zhang X, Zeng Y, Wu R, Ding L, Xia Y, et al. [(18)F]FAPI-42 PET/CT versus [(18)F]FDG PET/CT for imaging of recurrent or metastatic gastrointestinal stromal tumors. Eur J Nucl Med Mol Imaging. 2022;50(1):194–204.

    CAS  PubMed  Google Scholar 

  18. Guo W, Pang Y, Yao L, Zhao L, Fan C, Ke J, et al. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [(68)Ga]Ga-FAPI-04 PET/CT versus MRI and [(18)F]-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2021;48(5):1604–17.

    CAS  PubMed  Google Scholar 

  19. Shi X, Xing H, Yang X, Li F, Yao S, Congwei J, et al. Comparison of PET imaging of activated fibroblasts and (18)F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2021;48(5):1593–603.

    CAS  PubMed  Google Scholar 

  20. Kömek H, Can C, Güzel Y, Oruç Z, Gündoğan C, Yildirim ÖA, et al. 68Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET/CT. Ann Nucl Med. 2021;35(6):744–52.

    PubMed  Google Scholar 

  21. Dendl K, Koerber SA, Finck R, Mokoala KMG, Staudinger F, Schillings L, et al. (68)Ga-FAPI-PET/CT in patients with various gynecological malignancies. Eur J Nucl Med Mol Imaging. 2021;48(12):4089–100.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Zheng W, Liu L, Feng Y, Wang L, Chen Y. Comparison of 68 Ga-FAPI-04 and Fluorine-18-fluorodeoxyglucose PET/computed tomography in the detection of ovarian malignancies. Nucl Med Commun. 2023;44(3):194–203.

    CAS  PubMed  Google Scholar 

  23. Matrasova I, Busek P, Balaziova E, Sedo A. Heterogeneity of molecular forms of dipeptidyl peptidase-IV and fibroblast activation protein in human glioblastomas. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017;161(3):252–60.

    PubMed  Google Scholar 

  24. Röhrich M, Loktev A, Wefers AK, Altmann A, Paech D, Adeberg, et al. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT. Eur J Nucl Med Mol Imaging. 2019;46(12):2569–80.

    PubMed  Google Scholar 

  25. Chen X, Wang S, Lai Y, Wang G, Wei M, Jin X, et al. Fibroblast activation protein and glycolysis in lymphoma diagnosis: comparison of 68Ga-FAPI PET/CT and 18F-FDG PET/CT. J Nuc Med. 2023;64:1399–405.

    CAS  Google Scholar 

  26. Elboga U, Sahin E, Cayirli YB, Okuyan M, Aktas G, Haydaroglu Sahin H, et al. Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience. Tomography. 2022;8(1):293–302.

    PubMed  PubMed Central  Google Scholar 

  27. Zhao L, Pang Y, Luo Z, Fu K, Yang T, Zhao L, et al. Role of [(68)Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [(18)F]-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2021;48(6):1944–55.

    CAS  PubMed  Google Scholar 

  28. Gu B, Liu X, Wang S, Xu X, Liu X, Hu S, et al. Head-to-head evaluation of [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma. Eur J Nucl Med Mol Imaging. 2022;49(8):2889–901.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Chen H, Zhao L, Ruan D, Pang Y, Hao B, Dai Y, et al. Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings. Eur J Nucl Med Mol Imaging. 2021;48(1):73–86.

    PubMed  Google Scholar 

  30. Dendl K, Finck R, Giesel FL, Kratochwil C, Lindner T, Mier W, et al. FAP imaging in rare cancer entities-first clinical experience in a broad spectrum of malignancies. Eur J Nucl Med Mol Imaging. 2022;49(2):721–31.

    CAS  PubMed  Google Scholar 

  31. Pabst KM, Trajkovic-Arsic M, Cheung PFY, Ballke S, Steiger K, Bartel T, et al. Superior tumor detection for 68Ga-FAPI-46 versus 18F-FDG PET/CT and conventional CT in patients with cholangiocarcinoma. J Nucl Med. 2023;64(7):1049–55.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Unterrainer LM, Lindner S, Eismann L, Casuscelli J, Gildehaus FJ, Bui VN, et al. Feasibility of [68Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma. Eur J Nucl Med Mol Imaging. 2022;49(10):3571–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Koerber SA, Finck R, Dendl K, Uhl M, Lindner T, Kratochwil C, et al. Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT. Eur J Nucl Med Mol Imaging. 2021;48(12):3918–24.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Kratochwil C, Giesel FL, Rathke H, Fink R, Dendl K, Debus J, et al. [153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma. Eur J Nucl Med Mol Imaging. 2021;48(9):3011–3.

    PubMed  PubMed Central  Google Scholar 

  35. Ferdinandus J, Costa PF, Kessler L, Weber M, Hirmas N, Kostbade K, et al. Initial clinical experience with 90Y-FAPI-46 radioligand therapy for advanced-stage solid tumors: a case series of 9 patients. J Nucl Med. 2022;63(5):727–34.

    PubMed  PubMed Central  Google Scholar 

  36. Kessler L, Ferdinandus J, Hirmas N, Zarrad F, Nader M, Kersting D, et al. Pitfalls and common findings in 68Ga-FAPI PET: a pictorial analysis. J Nucl Med. 2022;63(6):890–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Zhang X, Song W, Qin C, Liu F, Lan X. Non-malignant findings of focal 68Ga-FAPI-04 uptake in pancreas. Eur J Nucl Med Mol Imaging. 2021;48(8):2635–41.

    CAS  PubMed  Google Scholar 

  38. Kesch C, Yirga L, Dendl K, Handke A, Darr C, Krafft U, et al. High fibroblast activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics. Eur J Nucl Med Mol Imaging. 2021;49(1):385–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Kessel K, Seifert R, Weckesser M, Boegemann M, Huss S, Kratochwil C, et al. Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging. Ann Nucl Med. 2022;36(3):293–301.

    CAS  PubMed  Google Scholar 

  40. Isik EG, Has-Simsek D, Sanli O, Sanli Y, Kuyumcu S. Fibroblast activation protein-targeted PET imaging of metastatic castration-resistant prostate cancer compared with 68Ga-PSMA and 18F-FDG PET/CT. Clin Nucl Med. 2022;47(1):e54–5.

    PubMed  Google Scholar 

  41. Rosenkrans ZT, Massey CF, Bernau K, Ferreira CA, Jeffery JJ, Schulte JJ, et al. [(68) Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity. Eur J Nucl Med Mol Imaging. 2022;49(11):3705–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Hao B, Wu X, Pang Y, Sun L, Wu H, Huang W, et al. [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of tuberculous lesions. Eur J Nucl Med Mol Imaging. 2021;48(2):651–2.

    PubMed  Google Scholar 

  43. Zhou Y, Yang X, Liu H, Luo W, Liu H, Lv T, et al. Value of [(68)Ga]Ga-FAPI-04 imaging in the diagnosis of renal fibrosis. Eur J Nucl Med Mol Imaging. 2021;48(11):3493–501.

    CAS  PubMed  Google Scholar 

  44. Conen P, Pennetta F, Dendl K, Hertel F, Vogg A, Haberkorn U, et al. [(68) Ga]Ga-FAPI uptake correlates with the state of chronic kidney disease. Eur J Nucl Med Mol Imaging. 2022;49(10):3365–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Xie B, Wang J, Xi XY, Guo X, Chen BX, Li L, et al. Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: comparison with cardiac magnetic resonance imaging. Eur J Nucl Med Mol Imaging. 2022;49(8):2786–97.

    CAS  PubMed  Google Scholar 

  46. Zhang M, Quan W, Zhu T, Feng S, Huang X, Meng H, et al. [68Ga]Ga-DOTA-FAPI-04 PET/MR in patients with acute myocardial infarction: potential role of predicting left ventricular remodeling. Eur J Nucl Med Mol Imaging. 2023;50(3):839–48.

    CAS  PubMed  Google Scholar 

  47. Wang J, Huo L, Lin X, Fang L, Hacker M, Niu N, et al. Molecular imaging of fibroblast activation in multiple non-ischemic cardiomyopathies. EJNMMI Res. 2023;13(1):39.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Treutlein C, Distler JHW, Tascilar K, Fakhouri SC, Györfi AH, Atzinger A, et al. Assessment of myocardial fibrosis in patients with systemic sclerosis using [68Ga]Ga-FAPI-04-PET-CT. Eur J Nucl Med Mol Imaging. 2023;50(6):1629–35.

    CAS  PubMed  Google Scholar 

  49. Chen BX, Xing HQ, Gong JN, Guo XJ, Xi XY, Yang YH, et al. Imaging of cardiac fibroblast activation in patients with chronic thromboembolic pulmonary hypertension. Eur J Nucl Med Mol Imaging. 2022;49(4):1211–22.

    CAS  PubMed  Google Scholar 

  50. Heckmann MB, Reinhardt F, Finke D, Katus HA, Haberkorn U, Leuschner F, et al. Relationship between cardiac fibroblast activation protein activity by positron emission tomography and cardiovascular disease. Circ Cardiovasc Imaging. 2020;13(9):e010628.

    PubMed  PubMed Central  Google Scholar 

  51. Kupusovic J, Kessler L, Nekolla SG, Riesinger L, Weber MM, Ferdinandus J, et al. Visualization of thermal damage using (68) Ga-FAPI-PET/CT after pulmonary vein isolation. Eur J Nucl Med Mol Imaging. 2022;49(5):1553–9.

    CAS  PubMed  Google Scholar 

  52. Hotta M, Rieger AC, Jafarvand MG, Menon N, Farolfi A, Benz MR, et al. Non-oncologic incidental uptake on FAPI PET/CT imaging. Br J Radiol. 2023;96(1142):20220463.

    PubMed  Google Scholar 

  53. Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59(9):1415–22.

    CAS  PubMed  Google Scholar 

  54. Loktev A, Lindner T, Burger EM, Altmann A, Giesel F, Kratochwil C, et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J Nucl Med. 2019;60(10):1421–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Backhaus P, Gierse F, Burg MC, Buther F, Asmus I, Dorten P, et al. Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA. Eur J Nucl Med Mol Imaging. 2022;49(6):1822–32.

    CAS  PubMed  Google Scholar 

  56. Greifenstein L, Engelbogen N, Lahnif H, Sinnes JP, Bergmann R, Bachmann M, et al. Synthesis, labeling and preclinical evaluation of a squaric acid containing PSMA inhibitor labeled with 68Ga: a comparison with PSMA-11 and PSMA-617. ChemMedChem. 2020;15(8):695–704.

    CAS  PubMed  Google Scholar 

  57. Moon ES, Ballal S, Yadav MP, Bal C, Van Rymenant Y, Stephan S, et al. Fibroblast activation protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time. Am J Nucl Med Mol Imaging. 2021;11(6):476–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Lindner T, Altmann A, Giesel F, Kratochwil C, Kleist C, Kramer S, et al. 18F-labeled tracers targeting fibroblast activation protein. EJNMMI Radiopharm Chem. 2021;6(1):26.

    PubMed  PubMed Central  Google Scholar 

  59. Giesel FL, Adeberg S, Syed M, Lindner T, Jimenez-Franco LD, Mavriopoulou E, et al. FAPI-74 PET/CT using either 18F-AlF or Cold-Kit 68Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients. J Nucl Med. 2021;62(2):201–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Huang J, Fu L, Zhang X, Huang S, Dong Y, Hu K, et al. Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a [18F]-labeled glycopeptide-containing FAPI with [(18)F]FAPI-42. Eur J Nucl Med Mol Imaging. 2023;50:3363–74.

    CAS  PubMed  Google Scholar 

  61. Li H, Ye S, Li L, Zhong J, Yan Q, Zhong Y, et al. 18F- or 177Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retention. Eur J Nucl Med Mol Imaging. 2022;49(8):2705–15.

    CAS  PubMed  Google Scholar 

  62. Xu M, Chen J, Zhang P, Cai J, Song H, Li Z, et al. An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy. Eur J Nucl Med Mol Imaging. 2023;50:3214–24.

    CAS  PubMed  Google Scholar 

  63. Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E, et al. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging. 2022;49(11):3651–67.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan

    Yuji Nakamoto

  2. Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka, Japan

    Shingo Baba

  3. Department of Radiology, Kindai University Faculty of Medicine, Ohnohigashi 377-2, Osakasayama City, Osaka, 589-8511, Japan

    Hayato Kaida

  4. Department of Radiology, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama, 330-8503, Japan

    Osamu Manabe

  5. Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8675, Japan

    Tomoya Uehara

Authors
  1. Yuji Nakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shingo Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hayato Kaida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Osamu Manabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomoya Uehara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuji Nakamoto.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakamoto, Y., Baba, S., Kaida, H. et al. Recent topics in fibroblast activation protein inhibitor-PET/CT: clinical and pharmacological aspects. Ann Nucl Med 38, 10–19 (2024). https://doi.org/10.1007/s12149-023-01873-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-023-01873-6

Keywords

Search

Navigation